EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
EyePoint Pharmaceuticals, Inc. (EYPT) will participate in upcoming healthcare conferences to discuss their therapeutics for retinal diseases. Investors can access webcasts on the company's website.
02/27/2024 - 07:00 AM
WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that Company management will participate at the following upcoming conferences:
TD Cowen 44 th Annual Healthcare Conference Forum: Fireside Chat Date: Tuesday, March 5, 2024 Time: 10:30 a.m. ET
Leerink Partners Global Biopharma Conference Forum: 1x1 Investor Meetings Date: Monday, March 11, 2024
Guggenheim 5 th Annual Healthy Altitudes Summit Forum: Fireside Chat Date: Wednesday, March 13, 2024 Time: 9:15 a.m. ET
A webcast and subsequent archived replay of the presentations may be accessed via the Investors section of the Company website at www.eyepointpharma.com .
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, EYP-1901, is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™. Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
Investors: Christina Tartaglia Stern IR Direct: 212-698-8700christina.tartaglia@sternir.com
Media Contact Amy Phillips Green Room Communications Direct: 412-327-9499aphillips@greenroompr.com
When is EyePoint Pharmaceuticals participating in the TD Cowen 44th Annual Healthcare Conference Forum?
EyePoint Pharmaceuticals will participate in the TD Cowen 44th Annual Healthcare Conference Forum on Tuesday, March 5, 2024, at 10:30 a.m. ET.
Where can investors access webcasts of the presentations by EyePoint Pharmaceuticals?
Investors can access webcasts of the presentations by EyePoint Pharmaceuticals on the Investors section of the company's website at www.eyepointpharma.com.
What is the date and time of the Fireside Chat at the Guggenheim 5th Annual Healthy Altitudes Summit Forum?
The Fireside Chat at the Guggenheim 5th Annual Healthy Altitudes Summit Forum will take place on Wednesday, March 13, 2024, at 9:15 a.m. ET.
EyePoint Pharmaceuticals Inc
EYPT Rankings
#1302 Ranked by Stock Gains
EYPT Stock Data
Industry
Analytical Laboratory Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Analytical Laboratory Instrument Manufacturing
About EYPT
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®